Hemostod
HemostOD is a Swiss-based preclinical biotech company that engineers and manufactures universal platelets inspired by platelet biology to save lives. They develop innovative solutions for thrombocytopenia, tissue-targeted cargo delivery, regenerative medicine, and culture of therapeutic stem cells. Their proprietary platform enables scalable production of engineered platelets for various medical applications.
Industries
Nr. of Employees
small (1-50)
Hemostod
EPFL Innovation Park – Bâtiment M, Rue des Jordils, 1A, 1025 St-Sulpice, Switzerland
Patents
Products
Engineered universal platelets (HLA-null)
In vitro–manufactured platelets derived from an immortalized hematopoietic progenitor cell line, engineered to be HLA-null to reduce immune refractoriness and intended for transfusion use in thrombocytopenia.
Platelet-derived targeted delivery vehicles
Platelet-based carriers engineered to shield and deliver nucleic acids (miRNA/siRNA) or proteins to specific target tissues.
Platelet lysate for therapeutic stem cell culture
Platelet-derived lysate produced from engineered platelets intended as a supplement to boost proliferation of therapeutic stem cells in culture.
Engineered universal platelets (HLA-null)
In vitro–manufactured platelets derived from an immortalized hematopoietic progenitor cell line, engineered to be HLA-null to reduce immune refractoriness and intended for transfusion use in thrombocytopenia.
Platelet-derived targeted delivery vehicles
Platelet-based carriers engineered to shield and deliver nucleic acids (miRNA/siRNA) or proteins to specific target tissues.
Platelet lysate for therapeutic stem cell culture
Platelet-derived lysate produced from engineered platelets intended as a supplement to boost proliferation of therapeutic stem cells in culture.
Services
Joint development projects with clinical and transfusion partners to characterize engineered platelet products and advance them toward clinical evaluation.
Process development and scale-up activities in collaboration with specialized bioprocess centers to adapt laboratory methods for larger-scale production.
Joint development projects with clinical and transfusion partners to characterize engineered platelet products and advance them toward clinical evaluation.
Process development and scale-up activities in collaboration with specialized bioprocess centers to adapt laboratory methods for larger-scale production.
Expertise Areas
- Platelet biomanufacturing
- Cell line engineering and immortalization
- Megakaryocyte differentiation
- Targeted cargo delivery using cell-derived carriers
Key Technologies
- Microfluidic bioreactors for cell fragmentation
- Cell immortalization techniques
- Megakaryocyte differentiation protocols
- Genetic/cellular surface engineering
News & Updates
HemostOD received support from Venture Kick in two stages, including CHF 10,000 and CHF 40,000, to support its development.
HemostOD received a CHF 500,000 loan from the Fondation pour l’Innovation Technologique (FIT) to support its growth.
HemostOD announced a partnership with Interregional Blood Transfusion SRC to collaborate on in vitro production of platelets, aiming to develop universal platelet concentrates and move towards clinical trials.
HemostOD has been recognized as a promising healthcare company and will receive tailored support to grow.
HemostOD received support from Venture Kick in two stages, including CHF 10,000 and CHF 40,000, to support its development.
HemostOD received a CHF 500,000 loan from the Fondation pour l’Innovation Technologique (FIT) to support its growth.
HemostOD announced a partnership with Interregional Blood Transfusion SRC to collaborate on in vitro production of platelets, aiming to develop universal platelet concentrates and move towards clinical trials.
HemostOD has been recognized as a promising healthcare company and will receive tailored support to grow.